{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:06:54Z","timestamp":1761620814389,"version":"3.38.0"},"reference-count":0,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:p> Chronic hepatitis B infection is frequently diagnosed within the genitourinary clinic setting with sexual transmission the commonest route of acquisition in the United Kingdom. Only 3-5% of adults who contract acute hepatitis B will progress to chronic infection, and these individuals can be identified by the presence of hepatitis B surface antigen (HBsAg) in the bloodstream 6 months after infection. Individuals at highest risk of long-term complications such as cirrhosis and hepatocellular carcinoma, carry HBeAg and have high levels of circulating hepatitis B virus (HBV) deoxyribonucleic acid (DNA). Therapy should be targeted towards this group of patients. Two forms of therapy are now licensed for use in chronic hepatitis B infection: interferon-alpha and lamivudine. Seroconversion occurs in 30-40% of patients treated with interferon and treatment is often limited by toxicity. Lamivudine is well tolerated with seroconversion rates of 15-20% at one year, rising with increasing duration of therapy. Long-term monotherapy is limited however by the development of resistance mutations and combination nucleoside therapy is likely to become the treatment of choice in the future. Patients with chronic hepatitis B should be counselled regarding transmission, partner vaccination and alcohol intake and co-infection with other hepatitis viruses should be excluded. <\/jats:p>","DOI":"10.1258\/0956462011923273","type":"journal-article","created":{"date-parts":[[2002,10,16]],"date-time":"2002-10-16T09:48:30Z","timestamp":1034761710000},"page":"353-357","source":"Crossref","is-referenced-by-count":10,"title":["The management of chronic hepatitis B infection"],"prefix":"10.1177","volume":"12","author":[{"given":"G. V.","family":"Matthews","sequence":"first","affiliation":[{"name":"Department of HIV Medicine, Chelsea & Westminster Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of HIV Medicine, Chelsea & Westminster Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,6,1]]},"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462011923273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462011923273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:16:01Z","timestamp":1740960961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/0956462011923273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6,1]]}},"alternative-id":["10.1258\/0956462011923273"],"URL":"https:\/\/doi.org\/10.1258\/0956462011923273","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"type":"print","value":"0956-4624"},{"type":"electronic","value":"1758-1052"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}